Sven Klussmann is co-founder and Chief Scientific Officer of NOXXON Pharma AG, Berlin. He is a Biochemist by training and his initial studies were carried out at the Freie Universität Berlin, where he obtained his academic degrees. Dr. Klussmann received the Carl Ramsauer Award for his dissertation in which he demonstrated the principles of the Spiegelmer Technology, a new approach to identify biostable mirror-image oligonucleotides (so-called Spiegelmers) that can bind with high affinity to target molecules. He has authored more than 30 articles and 40 patents on oligonucleotides and their applications.